Chimera humanized vascular endothelial growth factor

a growth factor and humanized technology, applied in the field of chimera vascular endothelial growth factor, can solve the problems of disturbing vascularization therapy, causing patients to die, and causing a great deal of pain to patients
US20080319174A1Inactive Publication Date: 2008-12-25SHIBUYA MASABUMI
6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
SHIBUYA MASABUMI
Publication Date
2008-12-25
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

An object of the present invention is to provide a chimera VEGF-E having a reduced antigenicity while maintaining the activity of VEGF-E. The present invention provides a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF receptor-2) but does not bind to Flt-1 (VEGF, receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of application Ser. No. 10 / 343,825 which is a national stage of PCT / JP01 / 06856, filed Aug. 9, 2001, which claims priority to Japanese Application No. 2000-242629, filed Aug. 10, 2000. The disclosures of application Ser. No. 10 / 343,825 and PC / JP01 / 06856 are incorporated by reference herein in their entireties.TECHNICAL FIELD

[0002] The present invention relates to chimera vascular endothelial growth factors (VEGF). More particularly, the present invention relates to a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF receptor-2) but does not bind to Flt-1 (VEGF receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein. The present invention also relates to a medicament comprising the chimera protein, DNA encoding th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More